Friday, December 16, 2011

Stocks DD Cites: MNTA - Virdante acquistion

Read, understand and consent to the blog's disclaimer here before proceeding to read the article 

Did some digging to understand how Virdante fits with MNTA, and more so the potential products/bio-betters that they are looking at. In terms of alignment, both companies research is based of how sugar(glycosylation) affects protein function. In pre-clinical research, Virdante found a sugar called Sialic acid, the presence of which gives anti-inflammatory effects to the anti-bodies. In the absence of sialic acid, the anti-inflammatory effects were not seen in the anti-bodies. The below article mentions that one of the areas they are looking at is the following: "Sialating" m-AB's like Humira and Enbrel could potentially be increasing it's inflammatory properties(less dosage, as much as 10 times lesser, and hence potentially higher safety). Of-course, even if these efforts are successful, we are at least 5-6 years away from a market launch of such a bio-better.

No comments:

Post a Comment